GlassScriptPhysician profile
Grant W Mckenzie
NPI 1134651599
$3,972.55
in general payments reported to CMS, 2019-2025
28 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $143 · 2021: $788 · 2022: $725 · 2023: $1,527 · 2024: $653 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557 · Travel and Lodging: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.35 |
| Travel and Lodging | $759.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $1,079.60 | 2023 | |
| Novocure INC. | $739.83 | 2020-2024 | Optune |
| Gt Medical Technologies, INC | $357.74 | 2022-2024 | Gammatile |
| Astrazeneca Pharmaceuticals LP | $326.75 | 2021-2024 | Tagrisso, Enhertu |
| Coherus Oncology, INC. | $246.34 | 2021 | |
| Merck Sharp & Dohme LLC | $238.64 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Boston Scientific Corporation | $148.93 | 2021-2022 | |
| Monteris Medical Corporation | $129.73 | 2022 | |
| Alcresta Therapeutics, INC. | $124.53 | 2021 | |
| Incyte Corporation | $110.81 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Azurity Pharmaceuticals, INC. | $77.63 | 2023-2024 | Gliadel, Vivimusta |
| Bayer Healthcare Pharmaceuticals INC. | $50.73 | 2022-2025 | |
| Stemline Therapeutics INC. | $36.17 | 2023-2024 | Orserdu |
| Rigel Pharmaceuticals, INC. | $30.47 | 2023 | Rezlidhia, Tavalisse |
| Janssen Biotech, INC. | $29.08 | 2025 | Rybrevant |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $26.41 | 2021 | |
| Mirati Therapeutics, INC. | $21.86 | 2024 | Krazati |
| Ambu INC. | $21.35 | 2021 | |
| Seagen INC. | $20.89 | 2023 | Tukysa |
| Sumitomo Pharma America, INC. | $20.84 | 2024 | Orgovyx |
| Lilly USA, LLC | $20.77 | 2024 | Verzenio, Retevmo, Jaypirca |
| Foundation Medicine, INC. | $19.72 | 2023 | Foundationone Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $17.89 | 2024 | Alunbrig |
| G1 Therapeutics, INC. | $17.46 | 2023 | Cosela |
| Genentech USA, INC. | $16.19 | 2024 | Tecentriq |
| Aveo Pharmaceuticals, INC. | $15.26 | 2025 | |
| Amgen INC. | $13.99 | 2021 | |
| Genzyme Corporation | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.